WO2018151562A3 - Jnk 저해 활성을 갖는 신규한 벤즈이미다졸 유도체 및 이의 용도 - Google Patents

Jnk 저해 활성을 갖는 신규한 벤즈이미다졸 유도체 및 이의 용도 Download PDF

Info

Publication number
WO2018151562A3
WO2018151562A3 PCT/KR2018/001999 KR2018001999W WO2018151562A3 WO 2018151562 A3 WO2018151562 A3 WO 2018151562A3 KR 2018001999 W KR2018001999 W KR 2018001999W WO 2018151562 A3 WO2018151562 A3 WO 2018151562A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitory activity
benzimidazole derivative
novel benzimidazole
jnk
jnk inhibitory
Prior art date
Application number
PCT/KR2018/001999
Other languages
English (en)
French (fr)
Other versions
WO2018151562A2 (ko
WO2018151562A9 (ko
Inventor
하정미
양송이
Original Assignee
한양대학교 에리카산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한양대학교 에리카산학협력단 filed Critical 한양대학교 에리카산학협력단
Publication of WO2018151562A2 publication Critical patent/WO2018151562A2/ko
Publication of WO2018151562A3 publication Critical patent/WO2018151562A3/ko
Publication of WO2018151562A9 publication Critical patent/WO2018151562A9/ko
Priority to US16/544,029 priority Critical patent/US10781201B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

본 발명은 JNK (C-Jun N-terminal kinase) 저해 활성을 갖는 신규한 벤즈이미다졸 유도체 및 이의 용도에 관한 것이다. 본 발명에 따른 신규 벤즈이미다졸유도체 또는 이의 약학적으로 허용가능한 염은 JNK 3 (c-Jun N-terminal kinase 3)에 대한 우수한 저해 활성을 나타내는바, 퇴행성 뇌신경계 질환의 예방 또는 치료에 있어서, 보다 근본적으로 접근하여 타겟 치료할 수 있을 것으로 기대된다.
PCT/KR2018/001999 2017-02-20 2018-02-19 Jnk 저해 활성을 갖는 신규한 벤즈이미다졸 유도체 및 이의 용도 WO2018151562A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/544,029 US10781201B2 (en) 2017-02-20 2019-08-19 Benzimidazole derivative having JNK inhibitory activity and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170022188A KR101840674B1 (ko) 2017-02-20 2017-02-20 Jnk 저해 활성을 갖는 신규한 벤즈이미다졸 유도체 및 이의 용도
KR10-2017-0022188 2017-02-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/544,029 Continuation US10781201B2 (en) 2017-02-20 2019-08-19 Benzimidazole derivative having JNK inhibitory activity and use thereof

Publications (3)

Publication Number Publication Date
WO2018151562A2 WO2018151562A2 (ko) 2018-08-23
WO2018151562A3 true WO2018151562A3 (ko) 2018-12-13
WO2018151562A9 WO2018151562A9 (ko) 2019-01-10

Family

ID=61900488

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/001999 WO2018151562A2 (ko) 2017-02-20 2018-02-19 Jnk 저해 활성을 갖는 신규한 벤즈이미다졸 유도체 및 이의 용도

Country Status (3)

Country Link
US (1) US10781201B2 (ko)
KR (1) KR101840674B1 (ko)
WO (1) WO2018151562A2 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102514245B1 (ko) * 2019-12-03 2023-03-29 한양대학교 에리카산학협력단 단백질 인산화 효소 저해 활성을 갖는 신규한 피라졸 유도체 및 이의 용도
KR102510351B1 (ko) * 2020-02-28 2023-03-17 한양대학교 에리카산학협력단 단백질 인산화 효소 저해 활성을 갖는 신규한 이미다졸 유도체 및 이의 용도
KR102642716B1 (ko) * 2021-08-18 2024-03-04 한양대학교 에리카산학협력단 단백질 인산화 효소 저해 활성을 갖는 신규한 이미다졸 유도체 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000682A1 (en) * 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
KR20080015475A (ko) * 2005-07-01 2008-02-19 아이알엠 엘엘씨 단백질 키나제 억제제로서의 피리미딘-치환 벤즈이미다졸유도체
KR20140111521A (ko) * 2013-03-11 2014-09-19 한양대학교 에리카산학협력단 신규 벤즈이미다졸 유도체, 이의 이성질체 또는 이의 약학적으로 허용 가능한 염, 및 이를 포함하는 약학 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100337189B1 (ko) 1999-09-30 2002-05-18 복성해 인간세포의 인산화 효소 ｊｎｋ의 활성 조절인자로 작용하는 마우스의 ｓｋｉｐ 단백질 및 ｓｋｉｐ 유전자

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000682A1 (en) * 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
KR20080015475A (ko) * 2005-07-01 2008-02-19 아이알엠 엘엘씨 단백질 키나제 억제제로서의 피리미딘-치환 벤즈이미다졸유도체
KR20140111521A (ko) * 2013-03-11 2014-09-19 한양대학교 에리카산학협력단 신규 벤즈이미다졸 유도체, 이의 이성질체 또는 이의 약학적으로 허용 가능한 염, 및 이를 포함하는 약학 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIM, M. -H. ET AL.: "3D-QSAR Studies of 1,2-diaryl-1H-benzimidazole Derivatives as JNK3 Inhibitors with Protective Effects in Neuronal Cells", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 23, no. 6, 2013, pages 1639 - 1642, XP028986080 *
KIM, M. -H. ET AL.: "Syntheses and Biological Evaluation of 1-heteroaryl-2-aryl-1H- benzimidazole Derivatives as C-Jun N-terminal Kinase Inhibitors with Neuroprotective Effects", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 21, no. 8, 2013, pages 2271 - 2285, XP028596342 *

Also Published As

Publication number Publication date
KR101840674B1 (ko) 2018-03-21
WO2018151562A2 (ko) 2018-08-23
US20200039959A1 (en) 2020-02-06
WO2018151562A9 (ko) 2019-01-10
US10781201B2 (en) 2020-09-22

Similar Documents

Publication Publication Date Title
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
SA518400547B1 (ar) مشتقات بيرازولو بيريميدين كمثبط كيناز
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
MY195561A (en) Indole Carboxamide Compounds useful as Kinase Inhibitors
MX2017007976A (es) Compuestos inhibidores de parg.
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
MX2017007478A (es) Compuestos inhibidores.
WO2015194764A3 (ko) 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
PH12019502601A1 (en) Therapeutic compounds and compositions, and methods of use thereof
WO2015109340A3 (en) Vista antagonist and methods of use
WO2016126085A3 (ko) 헤테로 고리 화합물 및 그를 포함하는 약제학적 조성물
MY163235A (en) Pharmaceutical preparation containing pyridylaminoacetic acid compound
WO2018151562A3 (ko) Jnk 저해 활성을 갖는 신규한 벤즈이미다졸 유도체 및 이의 용도
EP3444330A4 (en) GENUSAGATHOBACULUM TRIBE
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
WO2016004413A3 (en) Gls1 inhibitors for treating disease
PH12021550122A1 (en) Solubilized apyrases, methods and use
MX2018009097A (es) Nuevo derivado de imidazol que tiene actividad inhibidora de jnk y uso del mismo.
MX2018011592A (es) Compuesto que tiene actividad inhibitoria de idh mutante, metodo de preparacion y usos del mismo.
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
WO2017117386A8 (en) Methods of treating cancer using network brakes
WO2020109233A3 (en) Trmt2a inhibitors for use in the treatment of polyglutamine diseases
WO2019014322A8 (en) KINASE INHIBITORS FOR THE TREATMENT OF DISEASES

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18754952

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18754952

Country of ref document: EP

Kind code of ref document: A2